+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

MacroGenics Inc (MGNX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 50 Pages
  • May 2024
  • GlobalData
  • ID: 4318238
MacroGenics Inc (MGNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MacroGenics Inc (MacroGenics) is a biopharmaceutical company which focuses on the development and delivery of novel antibody-based therapeutics for the treatment of cancer, infectious diseases and autoimmune disorders. Its product pipeline includes candidates for the treatment of solid tumors, HIV, breast and gastroesophageal cancers, type 1 diabetes, DART product candidates for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and b-cell malignancies. The company’s product candidates are based on proprietary technology platforms, namely, Cancer Stem Cell Platform, Dual-Affinity Re-Targeting (or DART) and TRIDENT Platform, and FC Optimization Platform. It works in collaboration with various pharmaceutical and biotechnology companies to leverage its technology platforms and protein engineering capabilities for development. MacroGenics is headquartered in Rockville, Maryland, the US.

MacroGenics Inc Key Recent Developments

  • May 09, 2024: MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
  • Mar 07, 2024: MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
  • Sep 05, 2023: Macrogenics Announces Achievement Of $15 Million Milestone Related To Gilead’s Nomination Of A Bispecific Research Program
  • Aug 09, 2023: MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • MacroGenics Inc - Key Facts
  • MacroGenics Inc - Key Employees
  • MacroGenics Inc - Key Employee Biographies
  • MacroGenics Inc - Major Products and Services
  • MacroGenics Inc - History
  • MacroGenics Inc - Company Statement
  • MacroGenics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • MacroGenics Inc - Business Description
  • R&D Overview
  • MacroGenics Inc - Corporate Strategy
  • MacroGenics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • MacroGenics Inc - Strengths
  • MacroGenics Inc - Weaknesses
  • MacroGenics Inc - Opportunities
  • MacroGenics Inc - Threats
  • MacroGenics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • MacroGenics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2024: MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
  • Mar 07, 2024: MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
  • Sep 05, 2023: Macrogenics Announces Achievement Of $15 Million Milestone Related To Gilead’s Nomination Of A Bispecific Research Program
  • Aug 09, 2023: MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
  • May 09, 2023: MacroGenics provides update on corporate progress and first quarter 2023 financial results
  • May 04, 2023: MacroGenics announces date of Q1 2023 financial results conference call
  • Mar 07, 2023: MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
  • Jan 04, 2023: MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • MacroGenics Inc, Key Facts
  • MacroGenics Inc, Key Employees
  • MacroGenics Inc, Key Employee Biographies
  • MacroGenics Inc, Major Products and Services
  • MacroGenics Inc, History
  • MacroGenics Inc, Subsidiaries
  • MacroGenics Inc, Key Competitors
  • MacroGenics Inc, Ratios based on current share price
  • MacroGenics Inc, Annual Ratios
  • MacroGenics Inc, Interim Ratios
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • MacroGenics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MacroGenics Inc, Performance Chart (2019 - 2023)
  • MacroGenics Inc, Ratio Charts
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • MacroGenics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co Inc
  • Eli Lilly and Co
  • Amgen Inc
  • Seagen Inc
  • AbbVie Inc
  • Regeneron Pharmaceuticals Inc
  • Genmab AS
  • Bristol-Myers Squibb Co
  • Zymeworks Inc
  • Shanghai Hengrui Pharmaceuticals Co Ltd
  • Pfizer Inc
  • Genentech USA Inc
  • Daiichi Sankyo Co Ltd
  • Affimed NV
  • Puma Biotechnology Inc
  • AstraZeneca Plc
  • Xencor Inc
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
  • Byondis BV